FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016132030> ?p ?o ?g. }

• W2016132030 endingPage "436" @default.
• W2016132030 startingPage "429" @default.
• W2016132030 abstract "In the European component of the Regional Resistance Surveillance study for 2011, a total of 21 countries were monitored for antimicrobial resistance patterns including Belgium, Bulgaria (BU), Croatia, Czech Republic, France (F), Germany (GE), Greece (GR), Ireland (IR), Israel (IS), Italy (IT), Poland (PO), Portugal (PT), Romania (RO), Russia (RU), Slovakia (SK), Slovenia, Spain, Sweden (SW), Turkey (T), Ukraine, and United Kingdom. Results from testing 12,572 strains (100 [BU] to 1535 [F] per nation) were interpreted by contemporary published breakpoints. Samples from 47 hospitals were reference tested against agents such as amikacin (AMK), cefoperazone/sulbactam (C/S), colistin (COL), levofloxacin, linezolid (LZD), tigecycline (TIG), vancomycin (VAN), and 21 others. Among Staphylococcus aureus, LZD (MIC90, 2 μg/mL), TIG (MIC90, 0.12 μg/mL), and VAN (MIC90, 1 μg/mL) exhibited complete coverage and methicillin resistance rates among nations (average, 31%) ranged from 0.9% (SW) to 60.0-60.2% (PT, SK). Seven LZD-resistant coagulase-negative staphylococci (only 1.1% resistance overall) were noted in 5 nations, and a Staphylococcus simulans strain (MIC, 8 μg/mL from RO) had L3 mutations (N130D, G152A, F147S, A157R); also 6 LZD-resistant enterococci were detected in 3 countries (GE, IR, T). VAN-resistant enterococci (10% overall; 84% VanA) were found in 14 countries, highest in GE and IR (23.0%). The ESBL phenotype rate for Escherichia coli was 20.1% (range, 0.9% [SW] to 70.0-89.7% [BU, RU]), best inhibited by COL (100.0% S), TIG (100.0%), AMK (83.3-94.1%), C/S (81.0%), and carbapenems (>99.0%; resistant strains in IS and T). Klebsiella spp. had greater ESBL rates (45.7% overall, range 2.5-100.0%), as well as carbapenem resistance (8.3% overall, greatest in BU, GR, IS, IT, PO, RO, RU, T). Non-fermentative Gram-negative bacilli (Pseudomonas aeruginosa, Acinetobacter [ACB]) were generally less susceptible, except against COL (99.2-99.6% S) and TIG (95.0% inhibited at ≤2 μg/mL; ACB only). The following carbapenemases were detected: VIM-1 (2 countries); IMP-1 (1 from T); KPC-2 or -3 (2 countries); VIM-4 (1 from PO), NDM-1 (2 in RO; 2 centers); and OXA-48 or -162 (5 from T; 2 centers). European surveillance sampling demonstrates a wide array of resistant isolates, less prevalent among Gram-positive cocci that remain inhibited by several available agents. However, beta-lactamase-mediated mechanisms have spread widely among Gram-negative bacilli, especially across the Eastern and Southern European nations, severely limiting infection chemotherapy and necessitating escalated antimicrobial stewardship." @default.
• W2016132030 created "2016-06-24" @default.
• W2016132030 creator A5026620873 @default.
• W2016132030 creator A5028739024 @default.
• W2016132030 creator A5041157580 @default.
• W2016132030 creator A5045535293 @default.
• W2016132030 creator A5056162570 @default.
• W2016132030 creator A5079430921 @default.
• W2016132030 date "2014-04-01" @default.
• W2016132030 modified "2023-09-28" @default.
• W2016132030 title "Resistance surveillance program report for selected European nations (2011)" @default.
• W2016132030 cites W1843492169 @default.
• W2016132030 cites W1854715522 @default.
• W2016132030 cites W1869453106 @default.
• W2016132030 cites W1893936760 @default.
• W2016132030 cites W1938922303 @default.
• W2016132030 cites W1972421353 @default.
• W2016132030 cites W2015811668 @default.
• W2016132030 cites W2019153470 @default.
• W2016132030 cites W2033074488 @default.
• W2016132030 cites W2064794566 @default.
• W2016132030 cites W2107352206 @default.
• W2016132030 cites W2119880192 @default.
• W2016132030 cites W2121254474 @default.
• W2016132030 cites W2123677996 @default.
• W2016132030 cites W2129071962 @default.
• W2016132030 cites W2129492211 @default.
• W2016132030 cites W2137202092 @default.
• W2016132030 cites W2154556219 @default.
• W2016132030 doi "https://doi.org/10.1016/j.diagmicrobio.2013.10.008" @default.
• W2016132030 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24440509" @default.
• W2016132030 hasPublicationYear "2014" @default.
• W2016132030 type Work @default.
• W2016132030 sameAs 2016132030 @default.
• W2016132030 citedByCount "77" @default.
• W2016132030 countsByYear W20161320302014 @default.
• W2016132030 countsByYear W20161320302015 @default.
• W2016132030 countsByYear W20161320302016 @default.
• W2016132030 countsByYear W20161320302017 @default.
• W2016132030 countsByYear W20161320302018 @default.
• W2016132030 countsByYear W20161320302019 @default.
• W2016132030 countsByYear W20161320302020 @default.
• W2016132030 countsByYear W20161320302021 @default.
• W2016132030 countsByYear W20161320302022 @default.
• W2016132030 countsByYear W20161320302023 @default.
• W2016132030 crossrefType "journal-article" @default.
• W2016132030 hasAuthorship W2016132030A5026620873 @default.
• W2016132030 hasAuthorship W2016132030A5028739024 @default.
• W2016132030 hasAuthorship W2016132030A5041157580 @default.
• W2016132030 hasAuthorship W2016132030A5045535293 @default.
• W2016132030 hasAuthorship W2016132030A5056162570 @default.
• W2016132030 hasAuthorship W2016132030A5079430921 @default.
• W2016132030 hasConcept C105639569 @default.
• W2016132030 hasConcept C144133560 @default.
• W2016132030 hasConcept C2777027569 @default.
• W2016132030 hasConcept C2777427914 @default.
• W2016132030 hasConcept C2778512257 @default.
• W2016132030 hasConcept C2778980435 @default.
• W2016132030 hasConcept C2779489039 @default.
• W2016132030 hasConcept C2781276175 @default.
• W2016132030 hasConcept C2781414143 @default.
• W2016132030 hasConcept C2910001868 @default.
• W2016132030 hasConcept C42972112 @default.
• W2016132030 hasConcept C501593827 @default.
• W2016132030 hasConcept C523546767 @default.
• W2016132030 hasConcept C54355233 @default.
• W2016132030 hasConcept C71924100 @default.
• W2016132030 hasConcept C86803240 @default.
• W2016132030 hasConcept C89423630 @default.
• W2016132030 hasConceptScore W2016132030C105639569 @default.
• W2016132030 hasConceptScore W2016132030C144133560 @default.
• W2016132030 hasConceptScore W2016132030C2777027569 @default.
• W2016132030 hasConceptScore W2016132030C2777427914 @default.
• W2016132030 hasConceptScore W2016132030C2778512257 @default.
• W2016132030 hasConceptScore W2016132030C2778980435 @default.
• W2016132030 hasConceptScore W2016132030C2779489039 @default.
• W2016132030 hasConceptScore W2016132030C2781276175 @default.
• W2016132030 hasConceptScore W2016132030C2781414143 @default.
• W2016132030 hasConceptScore W2016132030C2910001868 @default.
• W2016132030 hasConceptScore W2016132030C42972112 @default.
• W2016132030 hasConceptScore W2016132030C501593827 @default.
• W2016132030 hasConceptScore W2016132030C523546767 @default.
• W2016132030 hasConceptScore W2016132030C54355233 @default.
• W2016132030 hasConceptScore W2016132030C71924100 @default.
• W2016132030 hasConceptScore W2016132030C86803240 @default.
• W2016132030 hasConceptScore W2016132030C89423630 @default.
• W2016132030 hasIssue "4" @default.
• W2016132030 hasLocation W20161320301 @default.
• W2016132030 hasLocation W20161320302 @default.
• W2016132030 hasOpenAccess W2016132030 @default.
• W2016132030 hasPrimaryLocation W20161320301 @default.
• W2016132030 hasRelatedWork W1998609714 @default.
• W2016132030 hasRelatedWork W2053521393 @default.
• W2016132030 hasRelatedWork W2105149255 @default.
• W2016132030 hasRelatedWork W2116707625 @default.
• W2016132030 hasRelatedWork W2162513556 @default.
• W2016132030 hasRelatedWork W2352294271 @default.
• W2016132030 hasRelatedWork W2377551260 @default.

• next